The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to see how it compared to a one-time antibody injection ...

Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...